News, Events & Presentations News Menu Press Releases Events Calendar Presentations Year None2019201820172016 Date Title Sep 12, 2019 Castle Creek Pharmaceutical Holdings to Acquire Fibrocell Aug 14, 2019 Fibrocell Reports Second Quarter 2019 Financial Results and Recent Operational Highlights May 30, 2019 Fibrocell to Present at BIO International Convention 2019 May 29, 2019 Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB May 15, 2019 Fibrocell Reports First Quarter 2019 Financial Results and Recent Operational Highlights May 09, 2019 Fibrocell to Host Conference Call and Webcast on Wednesday, May 15, 2019 to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights Apr 15, 2019 Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy Apr 03, 2019 Fibrocell Announces Board Member Christine St.Clare Honored by National Association of Corporate Directors Mar 27, 2019 Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007 Mar 20, 2019 Fibrocell to Host Conference Call & Webcast for Full Year 2018 Financial Results and Recent Highlights on March 27, 2019 Feb 06, 2019 Fibrocell to Present at 21st Annual BIO CEO & Investor Conference Jan 16, 2019 Fibrocell to Present at Phacilitate Leaders World 2019
Aug 14, 2019 Fibrocell Reports Second Quarter 2019 Financial Results and Recent Operational Highlights
May 29, 2019 Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB
May 15, 2019 Fibrocell Reports First Quarter 2019 Financial Results and Recent Operational Highlights
May 09, 2019 Fibrocell to Host Conference Call and Webcast on Wednesday, May 15, 2019 to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights
Apr 15, 2019 Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy
Apr 03, 2019 Fibrocell Announces Board Member Christine St.Clare Honored by National Association of Corporate Directors
Mar 27, 2019 Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007
Mar 20, 2019 Fibrocell to Host Conference Call & Webcast for Full Year 2018 Financial Results and Recent Highlights on March 27, 2019
